Sionna Therapeutics, Inc. (NASDAQ:SION)
| Market Cap | $127.79M-93.6% |
| Revenue (ttm) | $0 |
| Net Income | -$109.52M-55.0% |
| EPS | -$2.44-52.2% |
| Shares Out | 45.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 547,657 |
| Open | $2.91 |
| Previous Close | $2.97 |
| Day's Range | $2.76 - $3.03 |
| 52-Week Range | $2.75 - $54.97 |
| Beta | 1.22 |
| Analysts | Hold |
| Price Target | $27.40(+869.91%) |
| Earnings Date | Mar 1, 2027 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating SION in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 1, 2027Earnings report
$SION stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SION holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SION's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SION Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SION patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SION from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SION
| VTIVanguard Morningstar Total Stock Market ETF | $2.85M |
| IWMiShares Russell 2000 ETF | $1.41M |
| VXFVanguard Extended Market ETF | $873.51K |
| IBBiShares Biotechnology ETF | $581.66K |
| IWOiShares Russell 2000 Growth ETF | $521.53K |
| VTWOVanguard Russell 2000 ETF | $460.94K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SION’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 22Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 0.10% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.08% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.07% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.01% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.00% |
| VHT | Vanguard Health Care ETF | 0.00% |
| FHLC | Fidelity MSCI Health Care Index ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
